Research programme: neurodegenerative disorder therapeutics - Celgene/EvotecAlternative Names: CureMN; CureMotorNeuron
Latest Information Update: 27 Dec 2016
At a glance
- Originator Evotec AG; Harvard Stem Cell Institute
- Developer Celgene Corporation; Evotec AG
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease; Amyotrophic lateral sclerosis; Parkinson's disease